Mr Jonathan B Skidmore > Norton Rose Fulbright > Dallas, United States > Lawyer Profile

D’Lesli M Davis heads up Norton Rose Fulbright‘s Texas-based life sciences and healthcare group that has national reach and provides comprehensive representation of clients in the sector in the defense of high-stakes litigation, as well as in relation to drug safety mandates. The team often has a lead role in large consolidated actions and MDLs and is able to marshal resources from its broader overarching product liability, mass torts and commercial litigation teams should the need arise. As well as handling conventional personal injury-related matters, Davis has been particularly effective in positioning the firm at the very pinnacle of cases relating to economic loss, not only behalf of affected consumers but also third party payers. Jonathan B Skidmore is noted for his trial expertise, as well as his ability to strategize in large-scale mass torts in the life sciences space, and senior associate Ellie Norris continues to impress for her pivotal work on big-ticket litigation, including on the discovery side, as well as working alongside expert and fact witnesses to ensure they persuasively advance the defense narrative.

Norton Rose Fulbright’s team advises biotech and bioscience companies, and retail pharmacies on routine merger clearances, ITC proceedings, and claims arising from data security breaches and privacy violations. D’Lesli M. Davis leads the team from Dallas alongside Jonathan B. Skidmore. Davis acts as trial counsel on behalf of medical device and pharmaceutical clients in mass tort cases and product liability litigation, while Skidmore handles a broad range of issues including drug safety, marketing, and discoveries. In the New York office, David Kessler heads the domestic data and information risk practice, advising clients on safe data storage and the integration of record retention. Also based in New York, Robin Adelstein acts as the US head for antitrust and competition at the firm, routinely assisting life sciences and pharmaceutical companies on M&A, trade association activities, and government investigations.